



NEW THERAPEUTICS FOR AGING DISEASES

[Press release](#)

BIOPHYTIS initiates the clinical batches production of BIO101, the first step in the ongoing phase 2b trial in the sarcopenic obesity

Biophytis appoints the American CMO Patheon for the manufacturing of BIO101

Romainville (France), September 21, 2015 – BIOPHYTIS (Alternext Paris: ALBPS), a biotech company specialized in the development of drug candidates to treat aging diseases, announces today that it has entered into an agreement for the production of clinical batches of BIO101 with Patheon, a U.S Contract Manufacturing Organization (CMO). This contract is a significant step in the ongoing phase 2b trial with BIO101 in the sarcopenic obesity.

The drug candidate BIO101 is a product (*Stemmacantha carthamoides*) that presents several favorable properties on muscle cells : it stimulates protein synthesis (hepatocytes, myocytes) and reveals hypoglycemiant and hypolipemiant effects.

Within the framework of this partnership, Patheon will handle the manufacturing of the clinical batches of BIO101. These batches will be used by BIOPHYTIS for the phase 2b test which will be launched in Europe soon after obtaining authorization from the regulatory authorities. This clinical trial will be the first one in the world to treat sarcopenic obese patients.

Stanislas Veillet, CEO of BIOPHYTIS commented: *"We are very proud to outsource the production of BIO101 to an internationally recognized CMO. This stage precedes the soon to come launch of our study of phase 2b of BIO101, our drug candidate for the treatment of the sarcopenic obese patients currently deprived of any therapeutic solution. The sarcopenic obesity that consists in an aggravated atrophy of skeletal muscles is dramatically expanding and affects 30 % of people over 60 years in the United States. BIOPHYTIS being the company the most advanced in this area, we have to select the best partners to keep our leadership "*

About sarcopenic obesity:

The sarcopenic obesity is a syndrome which affects an increasing number of aging people in overweight or obese and who present a stressed loss of skeletal muscles masked by the accumulation of fat masses.

The loss of mass and/or muscular strength increases the risk of falls and fractures and led to a progressive loss of mobility and autonomy.

The loss of the metabolic quality of the skeletal muscle, in particular its capacity to oxidize carbohydrates and lipids and to synthesize proteins increases considerably the risk of diabetes and cardiovascular diseases in the patients often already treated for the one or other one of these disorders: arterial hypertension, diabetes, heart failure.

The most exhaustive prevalence study based on the National Health and nutrition Survey III data (1988-1994) considers the proportion of obese sarcopenic subjects in 31 % of the whole population of more than 60 years, or approximately 20 million people concerned by this form of sarcopenia only in the U.S. The only available economic environmental study stated of a 18,5-billion-dollar cost for the U.S Health system (around 900 \$ a year by patient).

About BIOPHYTIS :

BIOPHYTIS is a biotech company founded in 2006 and specialized in aging diseases. It develops innovative therapeutic solutions on pathologies, without treatment, in order to restore the muscular and visual functions.

BIOPHYTIS focuses its R&D efforts in the fight against the age-related macular degeneration (AMD) and the age-related muscular dystrophy (Sarcopenia). On these two highly invalidating diseases, the company has proprietary candidates entering in phase 2b. Installed in the Biocitech technopark (Romainville-Paris), BIOPHYTIS has also a subsidiary in Brazil (Sao Paulo).

The company is based on leading research collaborations with the UPMC (Pierre et Marie Curie University), the ICAN (Institute of Cardiometabolism and Nutrition), the Institute of Myologie and the Vision Institute. BIOPHYTIS is a listed company on the Alternext by Euronext Paris market (ALBPS; ISIN: FR0012816825). **For more information, please visit: www.biophytis.com**

BIOPHYTIS is eligible for the French PEA-PME regime



Disclaimer :

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Listing Prospectus upon the admission of Company's shares for trading on the Alternext market of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or on BIOPHYTIS' website (www.biophytis.com). This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country.

Contacts :

BIOPHYTIS

Stanislas VEILLET

CEO

contact@biophytis.com

Tel : +33 (0) 1 1 41 83 66 00

Milestones – Press & Investors relations

Bruno ARABIAN

barabian@milestones.fr

Tel : +33 (0) 1 83 62 34 84 / +33 (0) 6 87 88 47 26